Ephedrine Sulfate

Narcolepsy, Migraine, Catarrh + 13 more

Treatment

20 Active Studies for Ephedrine Sulfate

What is Ephedrine Sulfate

Ephedrine

The Generic name of this drug

Treatment Summary

Pseudoephedrine is a drug related to ephedrine and is extracted from plants that have been used in traditional Eastern medicine for centuries. Pseudoephedrine was first studied in the West in 1889 and its decongestant effect on dogs was discovered in 1927. It works by affecting the sympathetic nervous system, but not as strongly as ephedrine.

Rynatuss

is the brand name

image of different drug pills on a surface

Ephedrine Sulfate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rynatuss

Ephedrine

1960

36

Effectiveness

How Ephedrine Sulfate Affects Patients

Pseudoephedrine helps to clear up congestion by narrowing blood vessels. It works quickly, but the effects may not last long unless it is taken as a special extended-release medication. Patients should be aware that taking pseudoephedrine can lead to stimulation of the central nervous system.

How Ephedrine Sulfate works in the body

Pseudoephedrine acts as a stimulant on your body, working on alpha and beta adrenergic receptors. This causes your blood vessels to narrow, making it useful for reducing congestion. It is also used to treat long-term erections. Pseudoephedrine also affects the way that hormones and neurotransmitters are transported throughout the body, increasing heart rate, blood pressure, and other bodily functions. It also blocks certain proteins from activating, which helps to reduce inflammation.

When to interrupt dosage

The suggested measure of Ephedrine Sulfate is contingent upon the diagnosed disorder, including Upper Respiratory Tract Infection, Airway secretion clearance therapy and Coughing. The quantity of dosage is contingent upon the method of delivery (e.g. Tablet, extended release or Oral) featured in the table beneath.

Condition

Dosage

Administration

Migraine

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Pharyngitis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Narcolepsy

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Myasthenia Gravis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Catarrh

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Acute Bronchitis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Depression

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Rhinorrhea

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Asthma

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Coughing

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Arthralgia

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Nasal Congestion

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Upper Respiratory Disease

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Hypotension

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Fever

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Hypersensitivity

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Tablet, coated - Oral, Tablet, coated, Tablet - Oral, Tablet, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Liquid, Solution, Nasal, Ointment, Ointment - Nasal, Capsule - Oral, Syrup - Oral, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Injection, Rectal, Suppository, Suppository - Rectal, Topical, Spray - Topical, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Liquid - Infiltration, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Bead - Oral, Bead, Injection - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Subcutaneous, Liquid - Nasal, Spray, Infiltration, Spray - Nasal

Warnings

Ephedrine Sulfate has five contraindications and should not be used while experiencing any of the conditions outlined in the table below.

Ephedrine Sulfate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ephedrine Sulfate.

Common Ephedrine Sulfate Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylamphetamine can be increased when used in combination with Ephedrine.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when used in combination with Ephedrine.

4-Bromo-2,5-dimethoxyamphetamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyamphetamine can be increased when used in combination with Ephedrine.

Acebutolol

Major

The therapeutic efficacy of Acebutolol can be increased when used in combination with Ephedrine.

Amphetamine/Dextroamphetamine

Major

The therapeutic efficacy of Amphetamine can be increased when used in combination with Ephedrine.

Ephedrine Sulfate Toxicity & Overdose Risk

The toxic dose of pseudoephedrine in rats is 2206mg/kg and 726mg/kg in mice. Symptoms of overdose may include dizziness, headache, nausea, vomiting, increased heart rate, chest pain, difficulty urinating, muscle weakness, anxiety, restlessness, insomnia, mental confusion, abnormal heart rhythms, loss of consciousness, seizures, and difficulty breathing. Treatment for an overdose should include supportive care and removal of the drug from the body.

Ephedrine Sulfate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ephedrine Sulfate?

270 active trials are currently investigating the potential of Ephedrine Sulfate to mitigate Allergic Reactions, Migraines, and Eye Ailments.

Condition

Clinical Trials

Trial Phases

Pharyngitis

0 Actively Recruiting

Myasthenia Gravis

17 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Arthralgia

0 Actively Recruiting

Rhinorrhea

0 Actively Recruiting

Fever

1 Actively Recruiting

Phase 4

Depression

288 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Hypotension

0 Actively Recruiting

Acute Bronchitis

8 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

Hypersensitivity

1 Actively Recruiting

Phase 4

Coughing

0 Actively Recruiting

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Asthma

1 Actively Recruiting

Phase 4

Upper Respiratory Disease

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Catarrh

0 Actively Recruiting

Migraine

15 Actively Recruiting

Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4

Ephedrine Sulfate Reviews: What are patients saying about Ephedrine Sulfate?

4.7

Patient Review

12/12/2008

Ephedrine Sulfate for Bronchitis

4.3

Patient Review

4/9/2009

Ephedrine Sulfate for Bronchitis

I had never tried Bronkaid before, but I decided to give it a shot since I was struggling with my asthmatic bronchitis. I'm really glad I did- within half an hour, I could tell that it was working better than any other over the counter medication I've used for this problem.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ephedrine sulfate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does ephedrine do to a person?

"The ephedrine alkaloids are weak stimulants that can mildly increase heart rate and blood pressure, as well as relaxing bronchial tissue to ease shortness of breath."

Answered by AI

Is ephedrine sulfate a stimulant?

"Ephedrine is a central nervous system (CNS) stimulant that has been used to prevent low blood pressure during anesthesia, as well as for asthma, narcolepsy, and obesity. While it is not the preferred treatment, it is still used for these purposes."

Answered by AI

How do you take ephedrine sulfate?

"Ephedrine sulfate injection must be diluted with normal saline or 5% dextrose in water before administration as an intravenous bolus to achieve the desired concentration."

Answered by AI

What is ephedrine sulfate used for?

"This drug is indicated for the treatment of allergic disorders such as bronchial asthma. It has been used as a pressor agent for a long time, particularly during spinal anesthesia when hypotension is common."

Answered by AI

Clinical Trials for Ephedrine Sulfate

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Image of Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry in Charleston, United States.

Mindfulness Training for Depression

18 - 70
All Sexes
Charleston, SC

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Healthy Minds smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

Waitlist Available
Has No Placebo

Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry

Clayton Olash, MD

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials
Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Peter Franzen

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Arizona State University in Phoenix, United States.

App-based Breathing Program for Migraine

18+
All Sexes
Phoenix, AZ

Migraine is one of the most common neurological disorders, characterized by recurrent headaches, sensitivity to light and movement, nausea, and autonomic dysregulation. Although mind-body interventions like biofeedback have shown their efficacy, they remain underutilized due to barriers such as transportation, time constraints, lack of awareness, stigma, and cost. A targeted approach to enhancing HRV is HRV biofeedback (HRVB), a technique using visual or auditory feedback to help people regulate HRV through slow-paced breathing and positive emotional regulation to promote ANS balance and emotional resilience. Investigators will conduct a remotely delivered pilot RCT of an 8-week, 10 min/day, novel app-based HRVB intervention compared to a sham control intervention (matching intervention time and attention with no biofeedback component) in adult with chronic migraine. Investigators hypothesize data collected from the study will: a) support the feasibility and acceptability of the remotely delivered app-based HRVB intervention among adults with chronic migraine, and b) provide insights into refining the intervention by examining patterns of change in migraine and psychological outcomes from pre- to post-intervention.

Waitlist Available
Online Trial

Arizona State University

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials